
- /
- Supported exchanges
- / US
- / VERU.NASDAQ
Veru Inc (VERU NASDAQ) stock market data APIs
Veru Inc Financial Data Overview
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Veru Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Veru Inc data using free add-ons & libraries
Get Veru Inc Fundamental Data
Veru Inc Fundamental data includes:
- Net Revenue: 16 886 K
- EBITDA: -38 166 728
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.05
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Veru Inc News

Veru Announces Novel Modified-Release Oral Formulation for Enobosarm
Veru Inc. VERU recently announced the selection of a novel modified-release oral formulation for enobosarm for chronic weight loss management. Enobosarm is a selective androgen receptor modulator (SAR...


Veru outlines Phase III plans for enobosarm and signals upcoming FDA clarity on lean mass preservation in obesity treatment
Earnings Call Insights: Veru Inc. (VERU) Q3 2025 MANAGEMENT VIEW * CEO Mitchell S. Steiner reported that Veru is focusing its late clinical-stage biopharmaceutical efforts on cardiometabolic and i...

Veru GAAP EPS of -$0.50 beats by $0.03
* Veru press release [https://seekingalpha.com/pr/20197066-veru-reports-fiscal-2025-third-quarter-financial-results-and-clinical-program-progress] (NASDAQ:VERU [https://seekingalpha.com/symbol/VERU]...

Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress
--Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal side...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.